Troubled Novelos touts promising breast cancer data

After suffering a serious setback when NOV-002 flunked a late-stage clinical trial for lung cancer earlier this year, Novelos says the same drug proved effective in combination with chemotherapy during a small Phase II trial for breast cancer. But the news failed to inspire much hope among disillusioned investors. Its shares (NVLT) were trading at 14 cents this morning. "We are excited about this proof of concept trial and we are excited to have NOV-002 back in the game," Novelos CEO Harry...